BRPI0920326A2 - composição e método para tratamento da síndrome do olho ressecado - Google Patents

composição e método para tratamento da síndrome do olho ressecado

Info

Publication number
BRPI0920326A2
BRPI0920326A2 BRPI0920326A BRPI0920326A BRPI0920326A2 BR PI0920326 A2 BRPI0920326 A2 BR PI0920326A2 BR PI0920326 A BRPI0920326 A BR PI0920326A BR PI0920326 A BRPI0920326 A BR PI0920326A BR PI0920326 A2 BRPI0920326 A2 BR PI0920326A2
Authority
BR
Brazil
Prior art keywords
composition
dry eye
eye syndrome
treating dry
treating
Prior art date
Application number
BRPI0920326A
Other languages
English (en)
Inventor
Louis L Wood
Vernon Wong
Original Assignee
Ramscor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramscor Inc filed Critical Ramscor Inc
Publication of BRPI0920326A2 publication Critical patent/BRPI0920326A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0920326A 2008-10-09 2009-10-09 composição e método para tratamento da síndrome do olho ressecado BRPI0920326A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10411008P 2008-10-09 2008-10-09
PCT/US2009/060200 WO2010042843A2 (en) 2008-10-09 2009-10-09 Composition and method for treating dry eye syndrome

Publications (1)

Publication Number Publication Date
BRPI0920326A2 true BRPI0920326A2 (pt) 2016-02-23

Family

ID=42099450

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920326A BRPI0920326A2 (pt) 2008-10-09 2009-10-09 composição e método para tratamento da síndrome do olho ressecado

Country Status (8)

Country Link
US (3) US8722728B2 (pt)
EP (1) EP2344155B1 (pt)
JP (2) JP5731980B2 (pt)
CN (2) CN107468648A (pt)
AU (1) AU2009302167B9 (pt)
BR (1) BRPI0920326A2 (pt)
CA (1) CA2739658C (pt)
WO (1) WO2010042843A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1888059T3 (pl) 2005-06-01 2015-06-30 Bioelectron Tech Corp Środki terapeutyczne aktywne wobec układów redoks do leczenia chorób mitochondrialnych i innych zaburzeń oraz modulacja biomarkerów energetycznych
JP5374162B2 (ja) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
MX2011002318A (es) 2008-09-10 2011-05-10 Edison Pharmaceuticals Inc Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
CA2739658C (en) * 2008-10-09 2016-11-08 Ramscor, Inc. Composition and method for treating dry eye syndrome
EP2424360A4 (en) * 2009-04-28 2012-10-03 Ampere Life Sciences Inc TOPICAL, PERIOCULAR OR INTRAOCULAR USE OF TOCOTRIENOLS FOR THE TREATMENT OF OPHTHALMIC DISEASES
EP2424495B1 (en) 2009-04-28 2018-01-17 Bioelectron Technology Corporation Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
RU2013152013A (ru) * 2011-04-22 2015-05-27 Алькон Рисерч, Лтд. Офтальмологическая композиция с системой увеличения вязкости, имеющей два различных увеличивающих вязкость агента
CN107106325B (zh) 2015-01-12 2021-05-25 科达莱昂治疗公司 微滴递送设备和方法
CN107530509A (zh) 2015-04-10 2018-01-02 科达莱昂治疗公司 具有可替换安瓿的压电分配器
CA3008849A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
WO2019005139A1 (en) * 2017-06-30 2019-01-03 Jenivision Inc. FORMULATIONS FOR HAIR GROWTH
CN107625824A (zh) * 2016-07-19 2018-01-26 姜先云 全功能渗出滴眼液中药
KR20190071674A (ko) * 2016-10-21 2019-06-24 라이온 가부시키가이샤 안과용 제제 및 안과용 약
KR102412086B1 (ko) 2017-01-20 2022-06-22 켄달리온 테라퓨틱스 인코포레이티드 압전 유체 분배기
EP3720397A4 (en) 2017-12-08 2021-08-11 Kedalion Therapeutics, Inc. SYSTEM FOR ALIGNMENT OF FLUID DISPENSING
AU2019262061A1 (en) 2018-05-01 2020-11-26 Chibi, Inc. Eye drop formulation and method for sustained delivery of medicament to the retina
CA3097927A1 (en) 2018-05-01 2019-11-07 Chibi, Inc. Liquid depot for non-invasive sustained delivery of agents to the eye
US10966948B2 (en) 2019-07-23 2021-04-06 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
CN112739337B (zh) 2018-07-27 2024-05-24 强生外科视力公司 用于治疗眼睛的组合物和方法
HRP20220180T1 (hr) * 2018-12-28 2022-04-29 Dr. Rolf Lambert Pharma-Consulting Gmbh Liposomska otopina kapi za oči i njihova uporaba za liječenje sindroma suhog oka
US11679028B2 (en) 2019-03-06 2023-06-20 Novartis Ag Multi-dose ocular fluid delivery system
US11969454B2 (en) 2019-11-19 2024-04-30 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
BR112022020948A2 (pt) 2020-04-17 2023-04-11 Kedallion Therapeutics Inc Sistema de distribuição livre de conservantes hidrodinamicamente atuado
US11938057B2 (en) 2020-04-17 2024-03-26 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
IT202100005777A1 (it) 2021-03-11 2022-09-11 Hippocrates Res S R L Composizione per l’uso nel trattamento dell’occhio secco

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62106018A (ja) * 1985-11-01 1987-05-16 Santen Pharmaceut Co Ltd 高濃度ビタミンｅ水性製剤
EP0708646A1 (en) * 1994-05-06 1996-05-01 Alcon Laboratories, Inc. Use of vitamin e tocopheryl derivatives in ophthalmic compositions
JPH09157165A (ja) * 1995-12-11 1997-06-17 Lion Corp 点眼薬及び白内障の遅延・治療用剤
ITMI981586A1 (it) 1998-07-10 2000-01-10 Giorgio Panin Vitamina e e suoi esteri per l'uso nel trattamento topico di patologie delle mucose
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
US6716451B1 (en) * 1999-11-30 2004-04-06 Soft Gel Technologies, Inc. Formulation and delivery method to enhance antioxidant potency of vitamin E
KR100365678B1 (ko) * 2000-03-24 2002-12-26 주식회사 엘지생명과학 주사능이 개선된 소마토트로핀 조성물
JP2004059432A (ja) * 2002-06-04 2004-02-26 Rohto Pharmaceut Co Ltd 角膜障害治療剤
JP2004323486A (ja) * 2003-04-30 2004-11-18 National Institute Of Advanced Industrial & Technology 網膜及び／又はブドウ膜疾患の予防乃至治療用点眼薬
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
KR101341359B1 (ko) * 2004-10-01 2013-12-13 램스코르 인코포레이티드 편리하게 이식가능한 서방형 약물 조성물
CA2605275C (en) * 2005-04-22 2015-06-30 Barrie Tan Use of vitamin e tocotrienols for the inhibition of intracellularly obligate pathogen chlamydia
WO2008002582A2 (en) * 2006-06-27 2008-01-03 Riolan Technologies, Inc. Ultraviolet absorbing ophthalmic compositions
JP5668476B2 (ja) * 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
CA2739658C (en) 2008-10-09 2016-11-08 Ramscor, Inc. Composition and method for treating dry eye syndrome

Also Published As

Publication number Publication date
US8722728B2 (en) 2014-05-13
CA2739658C (en) 2016-11-08
EP2344155A2 (en) 2011-07-20
EP2344155A4 (en) 2012-12-19
AU2009302167B2 (en) 2014-05-01
JP5731980B2 (ja) 2015-06-10
US20140200268A1 (en) 2014-07-17
US9474736B2 (en) 2016-10-25
WO2010042843A3 (en) 2010-07-01
CN102238949A (zh) 2011-11-09
US20150359779A1 (en) 2015-12-17
AU2009302167A1 (en) 2010-04-15
CA2739658A1 (en) 2010-04-15
AU2009302167B9 (en) 2014-05-29
JP2012505244A (ja) 2012-03-01
CN107468648A (zh) 2017-12-15
JP2015120712A (ja) 2015-07-02
US20100093845A1 (en) 2010-04-15
US9144566B2 (en) 2015-09-29
WO2010042843A2 (en) 2010-04-15
EP2344155B1 (en) 2017-09-06

Similar Documents

Publication Publication Date Title
BRPI0920326A2 (pt) composição e método para tratamento da síndrome do olho ressecado
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
BRPI0819331A2 (pt) Métodos e composições para o tratamento do olho seco
BRPI0923883A2 (pt) Aparelho e método para combinação de componentes para artigos de fumar
BR112014014234A2 (pt) composição não colorante para tratar as fibras queratínicas e método para tratar as fibras queratínicas
BRPI0922122A2 (pt) composições e métodos para tratamento de doença celíaca.
BRPI0912867A2 (pt) composição de tratamento para lavagem e método caseiro para tratamento de têxteis
BRPI0807918A2 (pt) composições e método para preservação de tecido
BRPI0908854A2 (pt) composições e métodos para o tratamento de tumor de origem hematopoética
BRPI0919575A2 (pt) método, e, composição
BRPI0920284A2 (pt) composição e método
BRPI0909627A2 (pt) métodos, composições e kits para tratar dores e pruridos
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
BRPI0810806A2 (pt) Método para tratar uma lesão cutânea em um indivíduo
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BRPI1007600A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
BRPI0823277A2 (pt) Composição, e , método
FI20070935A0 (fi) Koostumus ja menetelmä puun käsittelemiseksi
BRPI0919813A2 (pt) aparelho de exercício e método para operar aparelho de exercício
BRPI0921959A2 (pt) métodos e composições para remoção de tatuagem
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI0916787A2 (pt) artigo, e, método para fabricar um artigo
BRPI0822349A2 (pt) composições e métodos para tratar doenças lisossômicas
BRPI1006145A2 (pt) "composição e método para tratamento de diabetes".
BRPI0918646A2 (pt) aparelho e método para tratar choque acetebular femoral

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 10A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements